Advertisement
ACRS vs XTNT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Hold and XTNT is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRS’s FA Score shows that 0 FA rating(s) are green whileXTNT’s FA Score has 0 green FA rating(s).
- ACRS’s FA Score: 0 green, 5 red.
- XTNT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRS’s TA Score shows that 4 TA indicator(s) are bullish while XTNT’s TA Score has 4 bullish TA indicator(s).
- ACRS’s TA Score: 4 bullish, 4 bearish.
- XTNT’s TA Score: 4 bullish, 6 bearish.
Price Growth
ACRS (@Biotechnology) experienced а +10.90% price change this week, while XTNT (@Medical/Nursing Services) price change was +6.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.94%. For the same industry, the average monthly price growth was +6.51%, and the average quarterly price growth was -7.37%.
Reported Earning Dates
ACRS is expected to report earnings on Nov 11, 2026.
XTNT is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Biotechnology (+3.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical/Nursing Services (-0.94% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ACRS | XTNT | ACRS / XTNT | |
| Capitalization | 944M | 45.6M | 2,070% |
| EBITDA | -78.06M | 11.8M | -661% |
| Gain YTD | 112.957 | -58.559 | -193% |
| P/E Ratio | N/A | 44.60 | - |
| Revenue | 8.37M | 122M | 7% |
| Total Cash | 105M | 12.1M | 868% |
| Total Debt | N/A | 15.4M | - |
ACRS | XTNT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 19 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 85 | |
PRICE GROWTH RATING 1..100 | 35 | 88 | |
P/E GROWTH RATING 1..100 | 100 | 88 | |
SEASONALITY SCORE 1..100 | 32 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACRS's Valuation (50) in the Pharmaceuticals Other industry is in the same range as XTNT (73) in the Medical Specialties industry. This means that ACRS’s stock grew similarly to XTNT’s over the last 12 months.
ACRS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as XTNT (100) in the Medical Specialties industry. This means that ACRS’s stock grew similarly to XTNT’s over the last 12 months.
XTNT's SMR Rating (85) in the Medical Specialties industry is in the same range as ACRS (99) in the Pharmaceuticals Other industry. This means that XTNT’s stock grew similarly to ACRS’s over the last 12 months.
ACRS's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for XTNT (88) in the Medical Specialties industry. This means that ACRS’s stock grew somewhat faster than XTNT’s over the last 12 months.
XTNT's P/E Growth Rating (88) in the Medical Specialties industry is in the same range as ACRS (100) in the Pharmaceuticals Other industry. This means that XTNT’s stock grew similarly to ACRS’s over the last 12 months.
| ACRS | XTNT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 87% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 79% | 3 days ago 88% |
| Momentum ODDS (%) | 3 days ago 82% | 3 days ago 86% |
| MACD ODDS (%) | 3 days ago 74% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 84% | 3 days ago 86% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 87% |
| Advances ODDS (%) | 6 days ago 83% | 17 days ago 83% |
| Declines ODDS (%) | 17 days ago 82% | 12 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 83% | 3 days ago 89% |
| Aroon ODDS (%) | 3 days ago 72% | 3 days ago 87% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| ICBAX | 22.61 | 0.55 | +2.49% |
| ICON Natural Resources and Infras Inv | |||
| PZVEX | 17.58 | 0.23 | +1.33% |
| Pzena Emerging Markets Value Investor | |||
| SIVIX | 17.25 | 0.11 | +0.64% |
| State Street Instl Small-Cap Equity Inv | |||
| GTTRX | 41.10 | 0.24 | +0.59% |
| Goldman Sachs Small Cp Val Insghts R | |||
| FFMMX | 65.40 | 0.21 | +0.32% |
| American Funds American Mutual 529-F-2 | |||
XTNT and
Correlation & Price change
A.I.dvisor tells us that XTNT and STRRP have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XTNT and STRRP's prices will move in lockstep.
| Ticker / NAME | Correlation To XTNT | 1D Price Change % | ||
|---|---|---|---|---|
| XTNT | 100% | -2.52% | ||
| STRRP - XTNT | 31% Poorly correlated | +2.09% | ||
| CVRX - XTNT | 26% Poorly correlated | N/A | ||
| ACRS - XTNT | 25% Poorly correlated | +1.26% | ||
| MBOT - XTNT | 24% Poorly correlated | +0.67% | ||
| OM - XTNT | 24% Poorly correlated | -2.09% | ||
More | ||||